Goldman Sachs
-
Shenzhen-traded pharma firm prices Hong Kong IPO high -
Borrowers were scrambling to print trades with funding windows dwindling
-
However, deals are being downsized, while friends and family investors are being called in to help get them done
-
China-based biotechnology company is set to float on three different markets
-
First outing with new reference rate lands flat to just wide of fixed rate curve
-
Emerging markets bank one of just a handful of sizeable deals expected before 2022
-
Chinese trio launch IPOs, giving a fresh fillip to the city's equity capital market
-
Investors support the spin-off despite macroeconomic risks
-
Small, nimble trades set to typify SSA market as year draws to close
-
-
Bank was moved up to second bucket on the latest G-SIB list this week
-
Concessions remain high in IG corporate bonds as investors need jitters soothed
